Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of ChAd3-EBO-Z Ebola Vaccine in African Children
NCT02548078Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2015
- Primary completion
- May 2017
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
A Phase 2 trial of ChAd3-EBO-Z in Ebola virus disease (EVD), sponsored by GSK. Started Nov 2015; status: completed.
02
Drugs
ChAd3-EBO-Z
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT02548078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02548078.